ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2024-7-2-9-14ojrdrt-359Research ArticleЯДЕРНАЯ МЕДИЦИНАNUCLEAR MEDICINEПЭТ/КТ с 68Ga-DOTA-TATE и 68Ga-FAPI в диагностике нейроэндокринных опухолей. Клинические наблюденияPET/CT with 68Ga-DOTA-TATE and 68Ga-FAPI in the Diagnosis of Neuroendocrine Tumors. Clinical CasesБелкинЕ. В.BelkinE. V.

Белкин Егор Владимирович — ординатор отделения позитронной эмиссионной томографии НИИ КиЭР НМИЦ онкологии им. Н.Н. Блохина Минздрава России.

115478 Москва, Каширское шоссе, 24

Egor V. Belkin.

24 Kashirskoye Shosse, Moscow, 115478

ega.belkin@yandex.ruhttps://orcid.org/0000-0001-7226-5129ТулинП. Е.TulinP. E.

Тулин Павел Евгеньевич — к.м.н., с.н.с. отделения позитронной эмиссионной томографии НИИ КиЭР НМИЦ онкологии им. Н.Н. Блохина Минздрава России.

115478 Москва, Каширское шоссе, 24

Тел.: +79168709913

Pavel E. Tulin.

24 Kashirskoye Shosse, Moscow, 115478

480pol@mail.ruhttps://orcid.org/0000-0003-3576-6156ОджароваА. А.OdzharovaA. A.

Оджарова Акгуль Атаевна — к.м.н., с.н.с. отделения позитронной эмиссионной томографии НИИ КиЭР НМИЦ онкологии им. Н.Н. Блохина Минздрава России.

115478 Москва, Каширское шоссе, 24

Akgul A. Odzharova.

24 Kashirskoye Shosse, Moscow, 115478

odzharova07@yandex.ruНациональный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of OncologyRussian Federation20240407202472914Copyright © Белкин Е.В., Тулин П.Е., Оджарова А.А., 20242024Белкин Е.В., Тулин П.Е., Оджарова А.А.Belkin E.V., Tulin P.E., Odzharova A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/359Цель

Цель: Провести сравнительный анализ диагностической эффективности ПЭТ/КТ с 68Ga-DOTA-TATE и 68Ga-FAPI на примере клинических случаев НЭО (определение первичной опухоли и экстраорганных метастазов).

Материал и методы

Материал и методы: Двум пациентам с НЭО поджелудочной железы до лечения проведены ПЭТ/КТ-исследования с 68Ga-DOTA-TATE и 68Ga-FAPI. При ПЭТ/КТ с 68Ga-DOTA-TATE были успешно визуализированы первичные опухоли у обоих пациентов, получены данные о метастатическом процессе в печени у одного пациента. По данным ПЭТ/КТ с 68Ga-FAPI визуализация первичных опухолей была неоптимальна, метастазы в печени выявлены не были.

Заключение

Заключение: ПЭТ/КТ с 68Ga-DOTA-TATE является более эффективным методом радионуклидной диагностики НЭО, чем ПЭТ/КТ с 68Ga-FAPI.

Purpose

Purpose: To perform a comparative analysis of diagnostic efficiency of PET/CT with 68Ga-DOTA-TATE and 68Ga-FAPI on the example of clinical cases of NEO (detection of primary tumor and extra-organ metastases).

Material and methods

Material and methods: Two patients with pancreatic NEO underwent PET/CT studies with 68Ga-DOTA-TATE and 68Ga-FAPI before treatment. PET/CT with 68Ga-DOTA-TATE successfully visualized primary tumors in both patients; evidence of a metastatic process in the liver was obtained in one patient. PET/CT with 68Ga-FAPI showed non-optimal visualization of primary tumors, no liver metastases were detected.

Conclusion

Conclusion: PET/CT with 68Ga-DOTA-TATE is a more effective method of radionuclide diagnostics of NEO than PET/CT with 68Ga-FAPI.

НЭОПЭТ/КТ68Ga-DOTA-TATE68Ga-FAPIподжелудочная железаNETPET/CT68Ga-DOTA-TATE68Ga-FAPIpancreasReferencesTaal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004 Aug; 1:3-7. https://doi.org/10.1159/000080731.Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004 Aug; 1:3-7. https://doi.org/10.1159/000080731.Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008 Jan; 9(1):61- 72. https://doi.org/10.1016/s1470-2045(07)70410-2.Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008 Jan; 9(1):61- 72. https://doi.org/10.1016/s1470-2045(07)70410-2.Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci. 2004 Apr; 1014:13-27. https://doi.org/10.1196/annals.1294.002.Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci. 2004 Apr; 1014:13-27. https://doi.org/10.1196/annals.1294.002.Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun; 26(18):3063-72. https://doi.org/10.1200/JCO.2007.15.4377.Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun; 26(18):3063-72. https://doi.org/10.1200/JCO.2007.15.4377.Kulke MH. Somatostatin analogues in neuroendocrine tumors. J Natl Compr Canc Netw. 2016 Mar; 14(3):241-42. https://doi.org/10.6004/jnccn.2016.0029.Kulke MH. Somatostatin analogues in neuroendocrine tumors. J Natl Compr Canc Netw. 2016 Mar; 14(3):241-42. https://doi.org/10.6004/jnccn.2016.0029.Landerholm K, Falkmer S, Jarhult J. Epidemiology of small bowel carcinoids in a defined population. World J Surg. 2010 Jul; 34(7):1500-5. https://doi.org/10.1007/s00268-010-0519-z.Landerholm K, Falkmer S, Jarhult J. Epidemiology of small bowel carcinoids in a defined population. World J Surg. 2010 Jul; 34(7):1500-5. https://doi.org/10.1007/s00268-010-0519-z.Kerstrom G, Hellman P, Hessman O. Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol. 2005 Oct; 19(5):717-28. https://doi.org/10.1016/j.bpg.2005.05.005.Kerstrom G, Hellman P, Hessman O. Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol. 2005 Oct; 19(5):717-28. https://doi.org/10.1016/j.bpg.2005.05.005.Егоров АВ, Кузин НМ, Ветшев ПС и др. Спорные и нерешенные вопросы диагностики и лечения гормонопродуцирующих нейроэндокринных опухолей поджелудочной железы. Хирургия (Москва). 2005 Nov; (9):19-24.Egorov AV, Kuzin NM, Vetshev PS, et al. Controversial and unresolved issues of diagnosis and treatment of hormone-producing neuroendocrine tumors of the pancreas. Khirurgiia (Mosk). 2005 Nov; (9):19-24. (In Russ.).Gibril F, Jensen RT Somatostatin receptor scintigraphy in the Zollinger - Ellison syndrome. Ann Int Med. 1999 Oct; 2:179-85.Gibril F, Jensen RT Somatostatin receptor scintigraphy in the Zollinger - Ellison syndrome. Ann Int Med. 1999 Oct; 2:179-85.Thoeni RF, Mueller-Lisse UG, Chan R, et al. B Detection of small, functional islet tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology. 2000 Feb; 214(2):483-90. https://doi.org/10.1148/radiology.214.2.r00fe32483.Thoeni RF, Mueller-Lisse UG, Chan R, et al. B Detection of small, functional islet tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology. 2000 Feb; 214(2):483-90. https://doi.org/10.1148/radiology.214.2.r00fe32483.Ichikawa T, Peterson MS, Federle MP, et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology. 2000 Jul; 216(1):163-71. https://doi.org/10.1148/radiology.216.1.r00jl26163.Ichikawa T, Peterson MS, Federle MP, et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology. 2000 Jul; 216(1):163-71. https://doi.org/10.1148/radiology.216.1.r00jl26163.Raderer M, Kurtaran A, Leimer M, et al. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J Clin Oncol. 2000 Mar; 18(6):1331-6. https://doi.org/10.1200/JCO.2000.18.6.1331.Raderer M, Kurtaran A, Leimer M, et al. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J Clin Oncol. 2000 Mar; 18(6):1331-6. https://doi.org/10.1200/JCO.2000.18.6.1331.Lu SJ, Gnanasegaran G, Buscombe J, Navalkissoor S. Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: a review of the literature. Nucl Med Commun. 2013 Feb; 34(2):98-107. https://doi.org/10.1097/MNM.0b013e32835bd59d.Lu SJ, Gnanasegaran G, Buscombe J, Navalkissoor S. Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: a review of the literature. Nucl Med Commun. 2013 Feb; 34(2):98-107. https://doi.org/10.1097/MNM.0b013e32835bd59d.Kunikowska J, Lewington V, Krolicki L. Optimizing Somatostatin Receptor Imaging in Patients with Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTA-TATE PET/CT Upon Clinical Management. Clin Nucl Med. 2017 Dec; 42(12):905-11. https://doi.org/10.1097/RLU.0000000000001877.Kunikowska J, Lewington V, Krolicki L. Optimizing Somatostatin Receptor Imaging in Patients with Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTA-TATE PET/CT Upon Clinical Management. Clin Nucl Med. 2017 Dec; 42(12):905-11. https://doi.org/10.1097/RLU.0000000000001877.Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007 Jul; 34(7):982-93. https://doi.org/10.1007/s00259-006-0317-x.Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007 Jul; 34(7):982-93. https://doi.org/10.1007/s00259-006-0317-x.Baranova OD, Roumiantsev PO, Slashchuk KY, et al Radionuclide imaging and therapy in patients with neuroendocrine tumors. Endocrine Surgery. 2017; 11(4):178-90. https://doi.org/https://doi.org/10.14341/serg9572.Baranova OD, Roumiantsev PO, Slashchuk KY, et al Radionuclide imaging and therapy in patients with neuroendocrine tumors. Endocrine Surgery. 2017; 11(4):178-90. https://doi.org/https://doi.org/10.14341/serg9572.Farulla LSA, Demirci E, Castellucci P, et al. Radiolabeled FAP inhibitors as new pantumoral radiopharmaceuticals for PET imaging: a pictorial essay. Clin Transl Imaging. 2022 Aug; 11:95-106. https://doi.org/doi.org/10.1007/s40336-022-00506-8.Farulla LSA, Demirci E, Castellucci P, et al. Radiolabeled FAP inhibitors as new pantumoral radiopharmaceuticals for PET imaging: a pictorial essay. Clin Transl Imaging. 2022 Aug; 11:95-106. https://doi.org/doi.org/10.1007/s40336-022-00506-8.Lindner T, Loktev A, Altmann A, et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med. 2018 Sep; 59(9):1415-22. https://doi.org/doi.org/10.2967/jnumed.118.210443.Lindner T, Loktev A, Altmann A, et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med. 2018 Sep; 59(9):1415-22. https://doi.org/doi.org/10.2967/jnumed.118.210443.Treglia G, Muoio B, Roustaei H, et al. Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [18F] F-FDG in Oncology: A Systematic Review. Int J Mol Sci. 2021 Oct; 22(20):1-13. https://doi.org/doi.org/10.3390/ijms222011192.Treglia G, Muoio B, Roustaei H, et al. Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [18F] F-FDG in Oncology: A Systematic Review. Int J Mol Sci. 2021 Oct; 22(20):1-13. https://doi.org/doi.org/10.3390/ijms222011192.Ergul N, Yilmaz B, Cin M, et al. 68Ga-DOTA-FAPI-04 PET/ CT in Neuroendocrine Carcinoma of the Liver with Elevated AFP Level: Comparison with 18F-FDG PET/CT. Clin Nucl Med. 2022 Jan; 47(1):29-31. https://doi.org/10.1097/RLU.0000000000003811.Ergul N, Yilmaz B, Cin M, et al. 68Ga-DOTA-FAPI-04 PET/CT in Neuroendocrine Carcinoma of the Liver with Elevated AFP Level: Comparison with 18F-FDG PET/CT. Clin Nucl Med. 2022 Jan; 47(1):29-31. https://doi.org/10.1097/RLU.0000000000003811.Komek H, Gundogan C, Can C. 68Ga-FAPI PET/CT versus 68Ga-DOTATATE PET/CT in the evaluation of a patient with neuroendocrine tumor. Clin Nucl Med. 2021 May; 46(5):290-2. https://doi.org/10.1097/RLU.0000000000003490.Komek H, Gundogan C, Can C. 68Ga-FAPI PET/CT versus 68Ga-DOTATATE PET/CT in the evaluation of a patient with neuroendocrine tumor. Clin Nucl Med. 2021 May; 46(5):290-2. https://doi.org/10.1097/RLU.0000000000003490.

The authors declare that there are no conflicts of interest present.